COX8A and glioblastoma: Among these, bevacizumab, a humanized antibody targeted against VEGF-A, is the most frequently used antibody for GBM therapy; the effectivity of bevacizumab in GBM patients has been summarized in recent reviews [10, 11], while other monoclonal antibodies tested in GBM patients are targeted against the variant III of the epidermal growth factor receptor (EGFR-vIII), the vascular endothelial growth factor receptor (VEGFR), the Hepatocyte Growth Factor Receptor (HGFR), and other receptors overexpressed on GBM malignant cells [12–25].